Incyte will no longer allow 340B hospitals to have direct delivery of Opzelura products purchased at the 340B discount price to contract pharmacies.
Incyte Becomes 26th Drugmaker to Place Contract Pharmacy Restrictions
Drug manufacturer Incyte Corp. this week announced it will become the 26th drug manufacturer to restrict access to 340B pricing when [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.